Ebrahim Haroon, MD

One star
One star
One star
One star
One half star

Rating: 4.9 out of 5 (133 ratings)

Role

Psychiatry
Research Program

Cancer Prevention and Control
Practicing Since

1998

Call 404-778-5526

Background

Ebrahim Haroon, MD, is an attending psychiatrist at Emory Healthcare and serves as medical director of the Emory Behavioral Immunology Program. Dr. Harron is an associate professor in the Department of Psychiatry and Behavioral Sciences at Emory University School of Medicine.

Titles & Roles

Associate Professor, Department of Psychiatry and Behavioral Sciences

Emory University School of Medicine
Medical Director, Emory Behavioral Immunology Program

Emory University

Education & Training

Education

Residency, Psychiatry, 1998
Yale Psychiatric Institute
Internship, Psychiatry, 1995
Tufts - New England Medical Center
Medical Education, MBBS, 1981
Madurai Medical College

Board Certifications

Psychiatry
American Board of Psychiatry and Neurology, 2000

Professional Memberships

Dr. Haroon is a member of several institutional and national committees including the Cancer Prevention Control Research Program at Winship Cancer Institute of Emory University, Emory Institutional Review Board and the Awards Committee of Society for Biological Psychiatry.

Research

Dr. Haroon's research interests are in identifying early pathophysiological changes associated with depression secondary to psychosocial and medical disorders.

Publications

Title/Journal	Authors	Publication Date
Rewiring the brain: Inflammation's impact on glutamate and neural networks in depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology	E Haroon, AH Miller	11/01/2024
A randomized proof-of-mechanism trial of TNF antagonism for motivational deficits and related corticostriatal circuitry in depressed patients with high inflammation. Molecular psychiatry	MT Treadway, SM Etuk, JA Cooper, S Hossein, E Hahn, SA Betters, S Liu, AR Arulpragasam, BAM DeVries, N Irfan, MR Nuutinen, EC Wommack, BJ Woolwine, M Bekhbat, PA Kragel, JC Felger, E Haroon, AH Miller	09/17/2024
A randomized proof-of-mechanism trial of TNF antagonism for motivational anhedonia and related corticostriatal circuitry in depressed patients with high inflammation. Research square	M Treadway, S Etuk, J Cooper, S Hossein, E Hahn, S Betters, S Liu, A Arulpragasam, B DeVries, N Irfan, M Nuutinen, E Wommack, B Woolwine, M Bekhbat, P Kragel, J Felger, E Haroon, A Miller	03/05/2024
A Chart-Stimulated Recall Activity to Assess Psychiatry Residents' Treatment-Based, Clinical Reasoning Skills. Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry	JJ Rakofsky, HA Stoddard, E Haroon, AP Hermida, SM Debrey, AL Crowell, BW Dunlop	12/01/2023
Alterations of gray and white matter volumes and cortical thickness in treated HIV-positive patients. Magnetic resonance imaging	A Joy, R Nagarajan, ES Daar, J Paul, A Saucedo, SK Yadav, M Guerrero, E Haroon, P Macey, MA Thomas	01/01/2023
Correction to: Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study. Molecular psychiatry	M Bekhbat, Z Li, ND Mehta, MT Treadway, MJ Lucido, BJ Woolwine, E Haroon, AH Miller, JC Felger	10/01/2022
Functional connectivity in reward circuitry and symptoms of anhedonia as therapeutic targets in depression with high inflammation: evidence from a dopamine challenge study. Molecular psychiatry	M Bekhbat, Z Li, ND Mehta, MT Treadway, MJ Lucido, BJ Woolwine, E Haroon, AH Miller, JC Felger	10/01/2022
Transcriptomic signatures of psychomotor slowing in peripheral blood of depressed patients: evidence for immunometabolic reprogramming. Molecular psychiatry	M Bekhbat, DR Goldsmith, BJ Woolwine, E Haroon, AH Miller, JC Felger	12/01/2021
Kynurenines increase MRS metabolites in basal ganglia and decrease resting-state connectivity in frontostriatal reward circuitry in depression. Translational psychiatry	X Chen, DJ Beltran, VD Tsygankova, BJ Woolwine, T Patel, W Baer, JC Felger, AH Miller, E Haroon	09/04/2021
Aiding and Abetting Anhedonia: Impact of Inflammation on the Brain and Pharmacological Implications. Pharmacological reviews	MJ Lucido, M Bekhbat, DR Goldsmith, MT Treadway, E Haroon, JC Felger, AH Miller	07/01/2021
Gene signatures in peripheral blood immune cells related to insulin resistance and low tyrosine metabolism define a sub-type of depression with high CRP and anhedonia. Brain, behavior, and immunity	M Bekhbat, MT Treadway, DR Goldsmith, BJ Woolwine, E Haroon, AH Miller, JC Felger	08/01/2020
Protein and gene markers of metabolic dysfunction and inflammation together associate with functional connectivity in reward and motor circuits in depression. Brain, behavior, and immunity	DR Goldsmith, M Bekhbat, NA Le, X Chen, BJ Woolwine, Z Li, E Haroon, JC Felger	08/01/2020
What does plasma CRP tell us about peripheral and central inflammation in depression? Molecular psychiatry	JC Felger, E Haroon, TA Patel, DR Goldsmith, EC Wommack, BJ Woolwine, NA Le, R Feinberg, MG Tansey, AH Miller	06/01/2020
Beyond the looking glass: recent advances in understanding the impact of environmental exposures on neuropsychiatric disease. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology	JA Hollander, DA Cory-Slechta, FN Jacka, ST Szabo, TR Guilarte, SD Bilbo, CJ Mattingly, SS Moy, E Haroon, M Hornig, ED Levin, MV Pletnikov, JL Zehr, KA McAllister, AL Dzierlenga, AE Garton, CP Lawler, C Ladd-Acosta	06/01/2020
Associations among peripheral and central kynurenine pathway metabolites and inflammation in depression. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology	E Haroon, JR Welle, BJ Woolwine, DR Goldsmith, W Baer, T Patel, JC Felger, AH Miller	05/01/2020
Inflammatory markers are associated with psychomotor slowing in patients with schizophrenia compared to healthy controls. NPJ schizophrenia	DR Goldsmith, N Massa, BD Pearce, EC Wommack, A Alrohaibani, N Goel, B Cuthbert, M Fargotstein, JC Felger, E Haroon, AH Miller, E Duncan	04/01/2020
Why we do need a new gold open access journal called "Brain, Behavior, and Immunity - Health". Brain, behavior, and immunity	A Cattaneo, E Haroon, KP Su, CM Pariante	01/01/2020
OXTR methylation modulates exogenous oxytocin effects on human brain activity during social interaction. Genes, brain, and behavior	X Chen, S Nishitani, E Haroon, AK Smith, JK Rilling	01/01/2020
Autoimmune psychosis: an international consensus on an approach to the diagnosis and management of psychosis of suspected autoimmune origin. The lancet. Psychiatry	TA Pollak, BR Lennox, S Müller, ME Benros, H Prüss, L Tebartz van Elst, H Klein, J Steiner, T Frodl, B Bogerts, L Tian, L Groc, A Hasan, BT Baune, D Endres, E Haroon, R Yolken, F Benedetti, A Halaris, JH Meyer, H Stassen, M Leboyer, D Fuchs, M Otto, DA Brown, A Vincent, S Najjar, K Bechter	01/01/2020
Inflammation and decreased functional connectivity in a widely-distributed network in depression: Centralized effects in the ventral medial prefrontal cortex. Brain, behavior, and immunity	L Yin, X Xu, G Chen, ND Mehta, E Haroon, AH Miller, Y Luo, Z Li, JC Felger	08/01/2019
Association of baseline inflammatory markers and the development of negative symptoms in individuals at clinical high risk for psychosis. Brain, behavior, and immunity	DR Goldsmith, E Haroon, AH Miller, J Addington, C Bearden, K Cadenhead, T Cannon, B Cornblatt, D Mathalon, T McGlashan, L Seidman, M Tsuang, SW Woods, EF Walker, DO Perkins	02/01/2019
Glucose and lipid-related biomarkers and the antidepressant response to infliximab in patients with treatment-resistant depression. Psychoneuroendocrinology	M Bekhbat, K Chu, NA Le, BJ Woolwine, E Haroon, AH Miller, JC Felger	12/01/2018
Intranasal oxytocin modulates neural functional connectivity during human social interaction. American journal of primatology	JK Rilling, X Chen, X Chen, E Haroon	10/01/2018
Inflammation negatively correlates with amygdala-ventromedial prefrontal functional connectivity in association with anxiety in patients with depression: Preliminary results. Brain, behavior, and immunity	ND Mehta, E Haroon, X Xu, BJ Woolwine, Z Li, JC Felger	10/01/2018
What's CRP got to do with it? Tackling the complexities of the relationship between CRP and depression. Brain, behavior, and immunity	JC Felger, E Haroon, AH Miller	10/01/2018
Increased inflammation and brain glutamate define a subtype of depression with decreased regional homogeneity, impaired network integrity, and anhedonia. Translational psychiatry	E Haroon, X Chen, Z Li, T Patel, BJ Woolwine, XP Hu, JC Felger, AH Miller	09/10/2018
Antidepressant treatment resistance is associated with increased inflammatory markers in patients with major depressive disorder. Psychoneuroendocrinology	E Haroon, AW Daguanno, BJ Woolwine, DR Goldsmith, WM Baer, EC Wommack, JC Felger, AH Miller	09/01/2018
TNF-α and IL-6 are associated with the deficit syndrome and negative symptoms in patients with chronic schizophrenia. Schizophrenia research	DR Goldsmith, E Haroon, AH Miller, GP Strauss, PF Buckley, BJ Miller	09/01/2018
Temporal Profiles and Dose-Responsiveness of Side Effects with Escitalopram and Duloxetine in Treatment-Naïve Depressed Adults. Behavioral sciences (Basel, Switzerland)	PE Polychroniou, HS Mayberg, WE Craighead, JJ Rakofsky, V Aponte Rivera, E Haroon, BW Dunlop	07/17/2018
Intranasal oxytocin, but not vasopressin, augments neural responses to toddlers in human fathers. Hormones and behavior	T Li, X Chen, J Mascaro, E Haroon, JK Rilling	07/01/2017
Assessing Residents' Confidence in the Context of Pharmacotherapy Competence. Academic psychiatry : the journal of the American Association of Directors of Psychiatric Residency Training and the Association for Academic Psychiatry	JJ Rakofsky, SJ Garlow, E Haroon, AP Hermida, JQ Young, BW Dunlop	06/01/2017
Within vs. between-subject effects of intranasal oxytocin on the neural response to cooperative and non-cooperative social interactions. Psychoneuroendocrinology	X Chen, P Gautam, E Haroon, JK Rilling	04/01/2017
Inflammation Effects on Brain Glutamate in Depression: Mechanistic Considerations and Treatment Implications. Current topics in behavioral neurosciences	E Haroon, AH Miller	01/01/2017
Arginine Vasopressin Effects on Subjective Judgments and Neural Responses to Same and Other-Sex Faces in Men and Women. Frontiers in endocrinology	JK Rilling, T Li, X Chen, P Gautam, E Haroon, RR Thompson	01/01/2017
Inflammation Effects on Glutamate as a Pathway to Neuroprogression in Mood Disorders. Modern trends in pharmacopsychiatry	E Haroon, AH Miller	01/01/2017
Inflammation, Glutamate, and Glia: A Trio of Trouble in Mood Disorders. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology	E Haroon, AH Miller, G Sanacora	01/01/2017
The Immunology of Behavior-Exploring the Role of the Immune System in Brain Health and Illness. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology	AH Miller, E Haroon, JC Felger	01/01/2017
Therapeutic Implications of Brain-Immune Interactions: Treatment in Translation. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology	AH Miller, E Haroon, JC Felger	01/01/2017
Interferon-alpha-induced inflammation is associated with reduced glucocorticoid negative feedback sensitivity and depression in patients with hepatitis C virus. Physiology & behavior	JC Felger, E Haroon, BJ Woolwine, CL Raison, AH Miller	11/01/2016
Conceptual convergence: increased inflammation is associated with increased basal ganglia glutamate in patients with major depression. Molecular psychiatry	E Haroon, CC Fleischer, JC Felger, X Chen, BJ Woolwine, T Patel, XP Hu, AH Miller	10/01/2016
Inflammation is associated with decreased functional connectivity within corticostriatal reward circuitry in depression. Molecular psychiatry	JC Felger, Z Li, E Haroon, BJ Woolwine, MY Jung, X Hu, AH Miller	10/01/2016
Inflammatory markers are associated with decreased psychomotor speed in patients with major depressive disorder. Brain, behavior, and immunity	DR Goldsmith, E Haroon, BJ Woolwine, MY Jung, EC Wommack, PD Harvey, MT Treadway, JC Felger, AH Miller	08/01/2016
Effects of oxytocin and vasopressin on the neural response to unreciprocated cooperation within brain regions involved in stress and anxiety in men and women. Brain imaging and behavior	X Chen, PD Hackett, AC DeMarco, C Feng, S Stair, E Haroon, B Ditzen, G Pagnoni, JK Rilling	06/01/2016
Oxytocin and vasopressin effects on the neural response to social cooperation are modulated by sex in humans. Brain imaging and behavior	C Feng, PD Hackett, AC DeMarco, X Chen, S Stair, E Haroon, B Ditzen, G Pagnoni, JK Rilling	12/01/2015
A common oxytocin receptor gene (OXTR) polymorphism modulates intranasal oxytocin effects on the neural response to social cooperation in humans. Genes, brain, and behavior	C Feng, A Lori, ID Waldman, EB Binder, E Haroon, JK Rilling	09/01/2015
Risk and Resilience: Animal Models Shed Light on the Pivotal Role of Inflammation in Individual Differences in Stress-Induced Depression. Biological psychiatry	JC Felger, E Haroon, AH Miller	07/01/2015
Inhibition of tumor necrosis factor improves sleep continuity in patients with treatment resistant depression and high inflammation. Brain, behavior, and immunity	JF Weinberger, CL Raison, DB Rye, AR Montague, BJ Woolwine, JC Felger, E Haroon, AH Miller	07/01/2015
Neuroticism modulates the effects of intranasal vasopressin treatment on the neural response to positive and negative social interactions. Neuropsychologia	C Feng, AC DeMarco, E Haroon, JK Rilling	07/01/2015
Age-related increases in basal ganglia glutamate are associated with TNF, reduced motivation and decreased psychomotor speed during IFN-alpha treatment: Preliminary findings. Brain, behavior, and immunity	E Haroon, JC Felger, BJ Woolwine, X Chen, S Parekh, JR Spivey, XP Hu, AH Miller	05/01/2015
IFN-alpha-induced cortical and subcortical glutamate changes assessed by magnetic resonance spectroscopy. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology	E Haroon, BJ Woolwine, X Chen, TW Pace, S Parekh, JR Spivey, XP Hu, AH Miller	06/01/2014
Sex differences in the neural and behavioral response to intranasal oxytocin and vasopressin during human social interaction. Psychoneuroendocrinology	JK Rilling, AC DeMarco, PD Hackett, X Chen, P Gautam, S Stair, E Haroon, R Thompson, B Ditzen, R Patel, G Pagnoni	01/01/2014
Transcriptional signatures related to glucose and lipid metabolism predict treatment response to the tumor necrosis factor antagonist infliximab in patients with treatment-resistant depression. Brain, behavior, and immunity	D Mehta, CL Raison, BJ Woolwine, E Haroon, EB Binder, AH Miller, JC Felger	07/01/2013
Cytokine targets in the brain: impact on neurotransmitters and neurocircuits. Depression and anxiety	AH Miller, E Haroon, CL Raison, JC Felger	04/01/2013
A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers. JAMA psychiatry	CL Raison, RE Rutherford, BJ Woolwine, C Shuo, P Schettler, DF Drake, E Haroon, AH Miller	01/01/2013
Psychoneuroimmunology meets neuropsychopharmacology: translational implications of the impact of inflammation on behavior. Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology	E Haroon, CL Raison, AH Miller	01/01/2012

Ratings & Reviews

Patients who are treated in outpatient and inpatient environments are eligible to receive a survey related to their individual care. Displayed ratings and reviews are displayed for Providers who have received at least 30 returned surveys over a 12-month period and are related to all Care Provider related survey questions. To help our patients better understand our Transparency program (ratings and review), the motivations behind it, how ratings are calculated, why ratings and reviews are not published for every EHC Provider, and how this information can be helpful for our patients, please click here.

4.9	One star One star One star One star One half star	Provider showed concern
4.9	One star One star One star One star One half star	Provider explained things clearly
4.9	One star One star One star One star One half star	Provider discussed treatment options
4.9	One star One star One star One star One half star	Provider included you in decisions
4.8	One star One star One star One star One half star	Likelihood of recommending this provider

View Reviews


One star One star One star One star One star	11/19/2024	Dr. Haroon listens carefully and has provided extremely good therapies.
One star One star One star One star One star	07/10/2024	Dr. Haroon was quite personable and exceptionally knowledgeable. I would recommend him without reservation.
One star One star One star One star One star	04/06/2024	Always good
One star One star One star One star One star	10/31/2023	Dr. Haroom was so kind, informative and easy to talk to! He is obviously a compassionate person, but also provided so many helpful insights and suggestions.
One star One star One star One star One star	10/24/2023	This was exceptionally good visit. Maybe because I had something to talk about this time and some thoughts about it. I felt very heard and understood and Dr Haroom described back to me what I had been thru - very good visit!!!!
One star One star One star One star One star	10/03/2023	We always discuss my medication and how it is helping me deal with the stress of my everyday life.
One star One star One star One star One star	09/28/2023	Dr. Harron is excellent
One star One star One star One star One star	09/28/2023	Dr Haroon is very thorough. His bedside manner is very comforting and supportive. I truly appreciate his communication with me, my primary care physician, Dr. Baker, and my full medical team.
One star One star One star One star One star	08/24/2023	Dr. Haroon has provided exceptional care during my time with him, and I would highly recommend him to anyone for treatment.
One star One star One star One star One star	06/23/2023	Very likely to continue my care at Emory
One star One star One star One star One star	01/29/2023	Dr Haroon was great. I trust him. We got along great. Similar opinions on my treatment! Exactly what I was looking for.